Further research is required to determine their efficacy in the delay or prevention of cancer onset in the carriers of germline BRCA1/BRCA2 variants, as well as to investigate their potential toxicity, risk of secondary cancer development and any mechanisms of resistance [91,92]. This evidence concerns the gene BRCA2 and cancer.